Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Leveraging Generative AI to Prioritize Drug Repurposing Candidates: Validating Identified Candidates for Alzheimer's Disease in Real-World Clinical Datasets.

medRxiv : the preprint server for health sciences·2023
Same author

Cardiac Sarcoidosis and a Likely Pathogenic <i>TTN</i> Variant in a Patient Presenting With Ventricular Tachycardia.

JACC. Case reports·2023
Same author

High-throughput functional mapping of variants in an arrhythmia gene, <i>KCNE1</i>, reveals novel biology.

bioRxiv : the preprint server for biology·2023
Same author

Detection of distant familial relatedness in biobanks for identification of undiagnosed carriers of a Mendelian disease variant: application to Long QT syndrome.

medRxiv : the preprint server for health sciences·2023
Same author

Multicenter clinical and functional evidence reclassifies a recurrent noncanonical filamin C splice-altering variant.

Heart rhythm·2023
Same author

Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results.

Circulation. Genomic and precision medicine·2023
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: May 8, 2026

Repeated Blood Collection for Blood Tests in Adult Zebrafish
06:17

Repeated Blood Collection for Blood Tests in Adult Zebrafish

Published on: August 30, 2015

37.0K

ファルマゲノミクス

Dan M Roden1, Howard L McLeod2, Mary V Relling3

  • 1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.

Lancet (London, England)
|August 10, 2019
PubMed
まとめ
この要約は機械生成です。

ゲノム医学は パーソナライズされた健康のために DNAの多様性を利用します この研究では,薬剤療法に合わせて遺伝子変異を利用し,そのメカニズム,臨床データ,実践における実施を調査しています.

さらに関連する動画

High-throughput Identification of Gene Regulatory Sequences Using Next-generation Sequencing of Circular Chromosome Conformation Capture 4C-seq
09:06

High-throughput Identification of Gene Regulatory Sequences Using Next-generation Sequencing of Circular Chromosome Conformation Capture 4C-seq

Published on: October 5, 2018

10.8K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.6K

関連する実験動画

Last Updated: May 8, 2026

Repeated Blood Collection for Blood Tests in Adult Zebrafish
06:17

Repeated Blood Collection for Blood Tests in Adult Zebrafish

Published on: August 30, 2015

37.0K
High-throughput Identification of Gene Regulatory Sequences Using Next-generation Sequencing of Circular Chromosome Conformation Capture 4C-seq
09:06

High-throughput Identification of Gene Regulatory Sequences Using Next-generation Sequencing of Circular Chromosome Conformation Capture 4C-seq

Published on: October 5, 2018

10.8K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.6K

科学分野:

  • ゲノム医学
  • 薬剤遺伝学
  • パーソナライズ された 治療

背景:

  • ゲノム医学はDNAの多様性を活用して 健康を改善することを目的としています
  • 遺伝子プロファイルに基づく 個別化薬物療法は 重要な目標です
  • 薬の作用の多様性を理解することは パーソナライズされた医療に不可欠です

研究 の 目的:

  • 薬物の作用の変動のメカニズムを見直す.
  • 薬動学と薬動力学における遺伝的変化の役割を探求する.
  • 臨床データと薬物遺伝学の実施を評価する.

主な方法:

  • 薬物の作用の多様性の一般的なメカニズムに関する文献レビュー.
  • 薬剤反応における遺伝的変化の役割の分析
  • 臨床試験のデータと実施戦略の検討

主要な成果:

  • 遺伝的多様性は 薬の有益な効果と有害な効果の両方に 影響を及ぼします
  • 薬剤濃度 (薬理動力学) と作用 (薬理動力学) の変動は遺伝的要因によって媒介される.
  • 臨床試験と実施のデータも収集されています.

結論:

  • 薬剤遺伝学は 薬物治療の個別化に 大きな希望を持っています
  • ゲノム医学が持つ可能性を 十分に発揮するには 更に研究と臨床的実施が必要です
  • 遺伝情報を臨床実践に組み込むことは 患者の治療結果を改善するために不可欠です